Research graph
References from CD20-positive multiple myeloma complicated by cold agglutinin disease. Local targets link to admitted publications; unresolved targets remain external evidence.
CD20 expression: a risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
10.3389/fonc.2022.1061438 · 2022 · External reference
Cold agglutinin disease
10.1182/blood-2013-02-474437 · 2013 · External reference
Immunohistochemical evaluation of CD20 expression in patients with multiple myeloma
10.1016/j.bjhh.2014.11.013 · 2015 · External reference
Differentiation stage of myelo-ma plasma cells: biological and clinical significance
10.1038/leu.2016.211 · 2017 · External reference
Unresolved reference
External reference
Cold agglutinin disease secondary to multiple myeloma in a psoriatic patient
10.3329/jom.v15i2.20688 · 2014 · External reference
Cold agglutinin disease
10.1182/asheducation-2016.1.226 · 2016 · External reference
10.1155/2019/1610632
10.1155/2019/1610632 · External reference
10.18502/crcp.v4i4.2387
10.18502/crcp.v4i4.2387 · External reference
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications
10.1097/00002371-200201000-00008 · 2002 · External reference
Anti-CD20 monoclonal antibody therapy in multiple myeloma
10.1111/j.1365-2141.2008.07024.x · 2008 · External reference
Ritux-imab in CD20 positive multiple myeloma
10.1038/sj.leu.2404558 · 2007 · External reference
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
10.1182/blood-2002-11-3333 · 2003 · External reference
10.1016/j.bbmt.2012.11.297
10.1016/j.bbmt.2012.11.297 · External reference
A case report and review of literature
10.1080/16078454.2023.2252651 · 2023 · External reference
10.1136/bcr-2022-251638
10.1136/bcr-2022-251638 · External reference
10.1016/j.bbmt.2012.11.297
10.1016/j.bbmt.2012.11.297 · ExternalCitation · doi-reference
Immunohistochemical evaluation of CD20 expression in patients with multiple myeloma
10.1016/j.bjhh.2014.11.013 · ExternalCitation · doi-reference
Differentiation stage of myelo-ma plasma cells: biological and clinical significance
10.1038/leu.2016.211 · ExternalCitation · doi-reference
Ritux-imab in CD20 positive multiple myeloma
10.1038/sj.leu.2404558 · ExternalCitation · doi-reference
A case report and review of literature
10.1080/16078454.2023.2252651 · ExternalCitation · doi-reference
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications
10.1097/00002371-200201000-00008 · ExternalCitation · doi-reference
Anti-CD20 monoclonal antibody therapy in multiple myeloma
10.1111/j.1365-2141.2008.07024.x · ExternalCitation · doi-reference
10.1136/bcr-2022-251638
10.1136/bcr-2022-251638 · ExternalCitation · doi-reference
10.1155/2019/1610632
10.1155/2019/1610632 · ExternalCitation · doi-reference
Cold agglutinin disease
10.1182/asheducation-2016.1.226 · ExternalCitation · doi-reference
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
10.1182/blood-2002-11-3333 · ExternalCitation · doi-reference
Cold agglutinin disease
10.1182/blood-2013-02-474437 · ExternalCitation · doi-reference
10.18502/crcp.v4i4.2387
10.18502/crcp.v4i4.2387 · ExternalCitation · doi-reference
Cold agglutinin disease secondary to multiple myeloma in a psoriatic patient
10.3329/jom.v15i2.20688 · ExternalCitation · doi-reference
CD20 expression: a risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
10.3389/fonc.2022.1061438 · ExternalCitation · doi-reference
